DSS, INC.

10% owner DSS, INC. sold 605,620 shares (605.6K shares) in 6 transactions across Mar 21-27 for $1,950,928.48 ($2.0M), reducing stake by -36.5%

DSS, INC., a 10% stakeholder, executed 6 separate sales totaling 605,620 shares for $1,950,928.48 across a 7-day window (March 21–27, 2025) at prices ranging from $2.50 to $3.30. This represents a -36.5% reduction in holdings, from 1,657,420 shares to 1,051,800 shares post-transaction. At a blended average price of $3.22, the insider was selling well above the current price of $1.52 (a $1.70 premium, or -69.4% from the 52-week high of $4.96). His prior 2 cross-ticker sells were well-timed (100% well-timed rate), with the most recent IBO sale on 2024-12-02 declining -45.5% over 90 days. However, context is critical: the company reported revenue of only $50,000.00 (latest quarter) against a market cap of $18,369,826.24 ($18.4M), and was unprofitable over its most recent full fiscal year. The timing and scale of this sale—executed at elevated prices relative to where the stock has since fallen—alongside the company's deteriorating fundamentals, merits investor attention.

10% owner DSS, INC. liquidates entire 53.1K share stake in IBO via 2 sales totaling 53,300 shares for $249,408.40

DSS, INC., a 10% holder, executed a complete exit of its position in Impact Biomedical, selling 53,300 shares (53.3K shares) across 2 separate transactions on 2024-12-02 and 2025-03-20 for $249,408.40, reducing holdings from 53.1K shares to zero. The timing of the larger sale on 2025-03-20 at $4.68 per share occurred within a context where the stock has posted significant recent momentum (+69.8% over 30 days, +151.8% over 90 days) and currently trades at $3.60, down 27.4% from its 52-week high of $4.96. This full liquidation by a significant shareholder represents a material reduction in insider ownership concentration and merits attention given the company's weak revenue base ($50.0K in the latest quarter), despite current profitability of $4.2M net income, and the insider's prior track record at this ticker (2 prior buys both showing negative 90-day returns) which shows no pattern of well-timed entries or exits at IBO.

10% owner DSS, INC. bought 1,000 shares of IBO at $2.33 (total $2,330.00)

DSS, INC., a 10% owner of Impact Biomedical Inc., purchased 1,000 shares at $2.33 on 2024-09-18, adding to existing holdings that now total 58,800 shares. This occurs in the context of a company trading at $2.52 just 4 trading days after its initial listing, with recent quarterly revenue of $50,000.00 but net income of -$884,000.00 and full-year profitability remaining negative. The purchase increases the insider's stake by 1.7% relative to pre-transaction holdings. Given the company's nascent public status, ongoing operating losses, and minimal revenue scale, investor attention should focus on whether this acquisition reflects meaningful confidence from an existing 10% holder or routine portfolio adjustments in an early-stage, unprofitable biomedical entity.

10% owner DSS Inc. buys 57,800 shares ($153.2K) in loss-making biomedical startup IBO (IPO day 3)

DSS, Inc., a 10% shareholder of Impact Biomedical Inc., purchased 57,800 shares across two transactions totaling $153,220.00 at blended average price $2.65 on 2024-09-16 and 2024-09-17. The company is in its third trading day following listing and is fundamentally unprofitable: quarterly revenue was $50,000.00 against net income of $-884,000.00, with negative net income over the most recent full fiscal year. The current price of $2.39 reflects a modest post-IPO pullback from the transaction prices ($2.69 and $2.40), placing the insider's cost basis slightly above current market. This accumulation by an established 10% stakeholder in an ultra-early-stage biomedical firm, while the company hemorrhages cash, represents a contrarian positioning into a highly speculative asset at or near IPO pricing with minimal operating revenue and persistent losses to examine.